Phosphodiesterase 6 (PDE6)

Phosphodiesterase 6 is an enzyme complex essential for the phototransduction cascade in vertebrate retinal photoreceptors[7]. It hydrolyzes cyclic GMP (cGMP), the second messenger responsible for keeping cGMP-gated ion channels open in darkness[1][7]. The PDE6 holoenzyme consists of two catalytic subunits (PDE6α and PDE6β in rods; combinations in cones) and two smaller inhibitory γ subunits (PDE6γ)[1][2][5][7]. Activation of PDE6 is mediated by the G protein transducin, which relieves inhibition by PDE6γ, allowing rapid hydrolysis of cGMP in response to light[1][5][7]. Structural studies reveal a complex architecture with regulatory GAF domains and finely tuned inter-subunit interactions that enable precise control of enzyme activity[1][4][5]. Mutations in PDE6 subunits are linked to various forms of inherited retinal degeneration, making it a critical molecular target in vision science and a potential target in retinal therapeutics[7]. Due to its structural similarity with PDE5, drugs like sildenafil and vardenafil developed for other targets can also inhibit PDE6, explaining certain drug-induced visual side effects[6][3].

Other names

Photoreceptor phosphodiesterasePDE6α (alpha subunit)PDE6β (beta subunit)PDE6γ (gamma subunit, regulatory)Rod cGMP phosphodiesteraseCone cGMP phosphodiesterase

Enzyme inhibition (competitive inhibition at active site by drugs such as sildenafil, vardenafil, zaprinast, IBMX, and tadalafil)[3][6]; Allosteric modulation (competition with regulatory γ subunit for active site binding)[3][6]